Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last […]
Compass Therapeutics (NASDAQ:CMPX – Get Rating) and BioAtla (NASDAQ:BCAB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Valuation & Earnings This table compares Compass Therapeutics and BioAtla’s […]
Compass Therapeutics (NASDAQ:CMPX – Get Rating) and BioAtla (NASDAQ:BCAB – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings. Institutional and Insider Ownership 54.3% of Compass Therapeutics shares are […]
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 in patients with advanced biliary tract cancers . Top line data is expected in the first half of 2024Continue to enroll in a U.S.. | May 4, 2023
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.